GlycoMimetics, Inc. Aktie News

GlycoMimetics, Inc. (NASDAQ:GLYC ) Corporate Update Call May 6, 2024 8:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Naureen Quibria - Capital One Securities Edward White - H.C. Wainwright Operator Good morning, and thank you for joining the GlycoMimetics Inve...

GlycoMimetics (NASDAQ: GLYC ) stock is taking a beating on Monday after the biotechnology company announced results from a Phase 3 clinical trial. Unfortunately for GLYC stockholders, this clinical trial failed to produce satisfactory results.

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML. In the study, uproleselan combined with chemotherapy did not achieve a sta...

GlycoMimetics is a biotech company focusing on developing a targeted therapy for acute myeloid leukemia. GLYC's lead candidate, uproleselan, has shown promising results in early-stage clinical trials for relapsed/refractory AML. The company is approaching a critical phase 3 data readout for uproleselan, which could significantly impact its valuation and potential for approval.

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of...

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023. Cash and cash equivalents as of December 31, 2023, were $41.8 million. “With the time-b...

GlycomiMetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. AML is a disease with a poor prognosis, especially for elderly patients, and there is a need for better treatment options. Uproleselan, a glycomimetic drug, aims to achieve minimal residual disease negativity and improve long-t...